ERIS Eris Lifesciences Q2 FY26 results (Jul–Sep 2025) and concall
ERIS delivered a steady Q2 with 10% domestic growth and significant margin expansion in the acquired Biocon portfolio. The company is pivoting toward a major international inflection point, backed by a massive surge in its EU-CDMO order book. While H1 saw some delays in price hikes and the cancellation of the gSaxenda launch, management remains bullish on the upcoming GLP-1 opportunity and vertical integration in insulin manufacturing.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| Revenue | 400 | 405 | 579 | 650 |
| EBITDA | 100 | 121 | 216 | 297 |
| Net profit | 2 | 30 | 100 | 150 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
